var data={"title":"Epoprostenol: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Epoprostenol: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6117?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=epoprostenol-drug-information\" class=\"drug drug_general\">see &quot;Epoprostenol: Drug information&quot;</a> and <a href=\"topic.htm?path=epoprostenol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Epoprostenol: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165855\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Flolan;</li>\n      <li>Veletri</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165856\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Caripul;</li>\n      <li>Flolan</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1011254\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Prostaglandin</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13908498\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Doses are expressed in units of <b>nanograms</b> (ng)/kg/minute. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pulmonary hypertension:</b> Very limited data available; efficacy results variable. <b>Note:</b> Avoid abrupt withdrawal or sudden large dose reductions when discontinuing therapy to prevent rebound pulmonary hypertension.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\"> Continuous IV infusion:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Low-dose regimen: Initial: 2 ng/kg/minute slowly titrated to 20 ng/kg/minute over ~3 hours was described in a single case report; epoprostenol was used in a full-term neonate (PNA: 72 hours) for PPHN refractory to inhaled nitric oxide and showed initial improvement in oxygenation index (Golzand 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">High-dose regimen: Initial: 20 ng/kg/minute, slowly titrated (according to oxygenation) at 30-minute intervals over 4 to 12 hours to a mean dose of 60 ng/kg/minute (range: 30 to 120 ng/kg/minute) and continued for a mean of 5.3 days (range: 3 to 10.5 days) was used in an open-label trial of eight neonates (GA: 34 to 42 weeks; PNA: 3 to 32 hours) with PPHN (excluding CHD and congenital diaphragmatic hernia) (Eronen 1997)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1011282\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=epoprostenol-drug-information\" class=\"drug drug_general\">see &quot;Epoprostenol: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Doses are expressed in units of <b>nanograms</b> (ng)/kg/minute.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pulmonary hypertension:</b> Infants, Children, Adolescents, and Adults: Continuous IV  infusion:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial: 1 to 2 ng/kg/minute, increase dose in increments of 1 to 2 ng/kg/minute every 15 minutes or longer until dose-limiting side effects are noted or tolerance limit to epoprostenol is observed </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dose adjustment:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Increase dose: 1 to 2 ng/kg/minute increments at intervals of at least 15 minutes if symptoms of pulmonary hypertension persist or recur following improvement. In clinical trials, dosing increases occurred at intervals of 24 to 48 hours or longer. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Decrease dose: 2 ng/kg/minute decrements at intervals of at least 15 minutes in case of dose-limiting pharmacologic (adverse) events. Avoid abrupt withdrawal or sudden large dose reductions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Chronic dosing: The need for increased doses should be expected with chronic use; incremental increases occur more frequently during the first few months after the drug is initiated. The optimal dose in children is not well defined. The mean chronic dose at 1 year of therapy is 20 to 40 ng/kg/minute in adults, but is 50-80 ng/kg/minute in children (particularly younger children); significant variability in optimal dose occurs in pediatric patients (Barst 1999; Rosenweig 1999; Widlitz 2003). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165839\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Flolan: 0.5 mg (1 ea); 1.5 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Veletri: 0.5 mg (1 ea); 1.5 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.5 mg (1 ea); 1.5 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165823\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11233737\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Orders for epoprostenol are distributed by two sources in the United States. Information on orders or reimbursement assistance may be obtained from either Accredo Health, Inc (1-866-344-4874) or CVS Caremark (1-877-242-2738). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1011285\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;\">Continuous IV infusion: Administer through a central venous catheter; peripheral infusion may be used temporarily until central line is established. Epoprostenol should be infused using an infusion pump through a dedicated lumen exclusive of any other drugs; consider a multilumen catheter if other IV medications are routinely administered. Use infusion sets with an in-line 0.22 micron filter for Veletri infusions. Flolan labeling does not specifically recommend filtering; however, the use of an in-line 0.22 micron filter was used during clinical trials. Avoid abrupt withdrawal, interruptions in delivery, or sudden large reductions in dosing. Patients should have access to a backup infusion pump and infusion sets. Patients may be discharged using an ambulatory infusion pump. Appropriate ambulatory infusion pump should be small and lightweight; be able to adjust infusion rates in 2 ng/kg/minute increments; have occlusion, end of infusion, and low battery alarms; have &plusmn; 6% accuracy of the programmed rate; and be positive continuous or pulsatile pressure-driven with intervals &le;3 minutes between pulses. The reservoir should be made of polypropylene, polyvinyl chloride, or glass. Immediate access to back up pump, infusion sets and medication is essential to prevent treatment interruptions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165850\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Flolan: </b>Prior to use, store intact vials and diluent at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F); do not freeze. Protect from light. Following reconstitution, solution must be stored at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) if not used immediately; do not freeze. Protect from light. Storage and administration limits for reconstituted solution are dependent on type of diluent use during reconstitution:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sterile diluent for Flolan:</b> When used at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F), reconstituted solutions are stable for up to 8 hours following reconstitution or removal from refrigerator. May also be stored for up to 40 hours at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) before use. When used with a cold pack, reconstituted solutions are stable for up to 24 hours; may also be stored at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) before use as long as the total time of refrigerated storage and infusion does not exceed 48 hours. Change cold packs every 12 hours. It is recommended to change cold pouches every 8 hours if room temperature approaches 30&deg;C (86&deg;F) (Flolan Canadian product labeling 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>pH 12 sterile diluent for Flolan:</b> Freshly prepared reconstituted solutions or reconstituted solutions that have been stored at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) for no longer than 8 days can be administered up to 72 hours at up to 25&deg;C (77&deg;F); 48 hours at up to 30&deg;C (86&deg;F); 24 hours at up to 35&deg;C (95&deg;F); 12 hours at up to 40&deg;C (104&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Veletri: </b>Prior to use, store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); do not freeze. Protect from light. Reconstituted vials must be further diluted prior to use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Caripul [Canadian product]:</b> Prior to use, store intact vials at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); do not freeze. Reconstituted vials must be further diluted prior to use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Reconstituted solutions of Veletri or Caripul immediately diluted with NS to a final concentration within a drug delivery reservoir may be administered immediately or stored at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) for up to 8 days; do not freeze. Protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>If administered immediately,</b> the following maximum durations of administration at room temperature (25&deg;C [77&deg;F]) according to solution concentration are recommended:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>US labeling (Veletri):</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">3,000 to &lt;15,000 ng/mL: 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">15,000 to &lt;60,000 ng/mL: 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ge;60,000 ng/mL: 72 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Canadian labeling (Caripul):</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">3,000 to &lt;15,000 ng/mL: 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ge;15,000: 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>If stored at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) for up to 8 days, </b> the following maximum durations of administration at room temperature (25&deg;C [77&deg;F]) according to solution concentration are recommended:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">3,000 to &lt;15,000 ng/mL: 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">15,000 to &lt;60,000 ng/mL: 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;60,000 ng/mL: 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Short excursions at 40&deg;C (104&deg;F) are permitted as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Solution concentration &lt;15,000 ng/mL: Up to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Solution concentration 15,000 to &lt;60,000 ng/mL: Up to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Solution concentration &ge;60,000 ng/mL: Up to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>The following maximum durations of administration at temperatures &gt;25&deg;C to 40&deg;C (&gt;77&deg;F up to 104&deg;F) administered either immediately or after up to 8 days storage at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) according to solution concentration are recommended: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Use at temperature &gt;25&deg;C to 30&deg;C (&gt;77&deg;F up to 86&deg;F):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>US labeling (Veletri):</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&lt;60,000 ng/mL: 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ge;60,000 ng/mL: 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Canadian labeling (Caripul): </i> All concentrations: 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Use at temperature up to 40&deg;C (104&deg;F):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>US labeling (Veletri):</i> &ge;60,000 ng/mL: 24 hours (immediately administered after preparation)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1011255\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Treatment of pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise capacity. <b>Note:</b> Efficacy has been established in patients with NYHA Class III or IV symptoms with idiopathic or heritable PAH or PAH associated with connective tissue diseases (FDA approved in adults) </p>\n    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">Has also been used diagnostically as a short-term IV infusion in patients with pulmonary hypertension in the cardiac catheterization laboratory to screen for responsiveness to other oral vasodilating agents (eg, calcium channel blockers). <b>Note:</b> Responsiveness to short-term (acute) IV infusions of epoprostenol predicts responsiveness to long-term treatment with oral calcium channel blockers; however, it does not predict responsiveness to long-term IV epoprostenol therapy. Patients who do not respond acutely to epoprostenol may respond to the drug when used chronically.</p>\n    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">Other potential uses include treatment of secondary pulmonary hypertension associated with ARDS, SLE, congenital heart disease, congenital diaphragmatic hernia, neonatal pulmonary hypertension, cardiopulmonary bypass surgery, hemodialysis, peripheral vascular disorders, portal hypertension, and neonatal purpura fulminans. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5174529\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165884\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;\">\n      <b>Note:</b> Adverse events reported during dose initiation and escalation include flushing, headache, nausea/vomiting, hypotension, anxiety/nervousness/agitation, chest pain; dizziness, abdominal pain, bradycardia, musculoskeletal pain, dyspnea, back pain, diaphoresis, dyspepsia, hypoesthesia/paresthesia, and tachycardia are also reported. Although some adverse reactions may be related to the underlying disease state, abdominal pain, anxiety/nervousness/agitation, arthralgia, bleeding, bradycardia, diarrhea, diaphoresis, flu-like syndrome, flushing, headache, hypotension, jaw pain, nausea, pain, pulmonary edema, rash, tachycardia, thrombocytopenia, and vomiting are clearly contributed to epoprostenol. The following adverse events have been reported during chronic administration for idiopathic or heritable PAH:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">Cardiovascular: Flushing, hypotension, tachycardia </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Agitation, anxiety, chills, dizziness, fever, flu-like syndrome, headache, nervousness, sepsis, tremor </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Dermal ulcer, eczema, skin rash, urticaria </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Anorexia, diarrhea, nausea, vomiting </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Injection site reactions: Infection, pain </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia, hyperesthesia, hypoesthesia, jaw pain, musculoskeletal pain, myalgia, neck pain, pain, paresthesia  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Abdominal pain, anemia, ascites, dyspnea, fatigue, hemorrhage, hepatic failure, hyperthyroidism, pancytopenia, pulmonary edema, pulmonary embolism, splenomegaly, thrombocytopenia </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165844\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to epoprostenol, to structurally-related compounds, or any component of the formulation; chronic use in patients with heart failure due to severe left ventricular systolic dysfunction; chronic use in patients who develop pulmonary edema during dose initiation (Veletri and Caripul [Canadian product] only).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165827\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary edema: Some patients with PAH have developed pulmonary edema during dosing adjustment and acute vasodilator testing (an off-label use), which may be associated with concomitant heart failure (LV systolic dysfunction with significantly elevated left heart filling pressures) or pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis. If pulmonary edema develops during therapy initiation, discontinue and do not readminister.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Rebound pulmonary hypertension: Avoid abrupt interruptions or large sudden reductions in dosage; may result in rebound pulmonary hypertension (eg, dyspnea, dizziness, asthenia). A fatal case occurred following interruption. Immediate access to medication or pump and infusion sets is essential to prevent treatment interruptions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vasodilation: Epoprostenol is a potent pulmonary and systemic vasodilator and can cause hypotension and other reactions such as flushing, nausea, vomiting, dizziness, and headache. Monitor blood pressure and symptoms regularly during initiation and after dose change.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Conditions that increase bleeding risk: Epoprostenol is a potent inhibitor of platelet aggregation. Use with caution in patients with other risk factors for bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate Use: Initiation or transition to epoprostenol requires specialized cardiopulmonary monitoring in a critical care setting where clinicians are experienced in advanced management of pulmonary arterial hypertension. To reduce the risk of thromboembolism during chronic use, anticoagulants should be coadministered unless contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infection: Chronic continuous IV infusion of epoprostenol via a chronic indwelling central venous catheter (CVC) has been associated with local infections and serious blood stream infections.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25872267\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Although the use of anticoagulants in adult patients with primary pulmonary hypertension has been shown to improve survival, such efficacy has not been demonstrated in pediatric patients. Some studies have reported the routine use of warfarin in pediatric patients receiving long-term (chronic) infusions of epoprostenol for pulmonary hypertension (Barst, 1999; Rosenzweig, 1999), while other studies have routinely discontinued anticoagulants prior to the initiation of epoprostenol therapy (Higenbottam, 1993). Epoprostenol is a potent inhibitor of platelet aggregation; monitor patients for bleeding, especially those with other risk factors or medications which may increase the risk for hemorrhage. Further studies are needed to assess the risks and benefits of routine anticoagulation in pediatric patients treated with epoprostenol.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299275\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165832\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13139&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Prostacyclin Analogues may enhance the antiplatelet effect of Agents with Antiplatelet Properties. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Prostacyclin Analogues may enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: Prostacyclin Analogues may enhance the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Digoxin: Epoprostenol may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: May enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165834\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2521390\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Women with pulmonary arterial hypertension (PAH) are encouraged to avoid pregnancy (McLaughlin 2009; Taichman 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1011287\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Hemodynamic effects (pulmonary vascular resistance, pulmonary arterial pressure, systemic blood pressure, heart rate). Monitor blood pressure (standing and supine) and heart rate closely for several hours following dosage adjustments. Monitor for improvements in exercise capacity, exertional dyspnea, fatigue, syncope, chest pain, and quality of life. Monitor the infusion pump device and catheters to avoid drug delivery system related failures. Monitor weight; serum potassium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165826\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Epoprostenol is also known as prostacyclin and PGI<sub>2</sub>. It is a strong vasodilator of all vascular beds. In addition, it is a potent endogenous inhibitor of platelet aggregation. The reduction in platelet aggregation results from epoprostenol's activation of intracellular adenylate cyclase and the resultant increase in cyclic adenosine monophosphate concentrations within the platelets. Additionally, it is capable of decreasing thrombogenesis and platelet clumping in the lungs by inhibiting platelet aggregation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165843\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Rapidly hydrolyzed; subject to some enzymatic degradation; forms two active metabolites (6-keto-prostaglandin F<sub>1</sub>&alpha; and 6,15-diketo-13,14-dihydro-prostaglandin F<sub>1</sub>&alpha;) with minimal activity and 14 inactive metabolites </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: ~6 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (84%); feces (4%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323130\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Epoprostenol Sodium Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (1): $19.44</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5 mg (1): $46.94</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Flolan Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (1): $22.43</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5 mg (1): $54.17</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Veletri Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (1): $28.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5 mg (1): $56.21</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038611\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Dynovase (ES);</li>\n      <li>Flolan (AT, AU, BE, CH, CZ, DK, EE, ES, FR, GB, GR, IE, IL, IT, LU, MT, NL, NO, PL, SG, TW);</li>\n      <li>Veletri (ES, GB, IE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Barst RJ, &quot;Pharmacologically Induced Pulmonary Vasodilatation in Children and Young Adults With Primary Pulmonary Hypertension,&quot; <i>Chest</i>, 1986, 89(4):497-503.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/2869919/pubmed\" target=\"_blank\" id=\"2869919\">2869919</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barst RJ, Maislin G, and Fishman AP, &quot;Vasodilator Therapy for Primary Pulmonary Hypertension in Children,&quot; <i>Circulation</i>, 1999, 99(9):1197-208.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/10069788 /pubmed\" target=\"_blank\" id=\"10069788 \">10069788 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barst RJ, Rubin LJ, Long WA, et al, &quot;A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) With Conventional Therapy for Primary Pulmonary Hypertension. The Primary Pulmonary Hypertension Study Group,&quot; <i>N Engl J Med</i>, 1996, 334(5):296-302.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/8532025/pubmed\" target=\"_blank\" id=\"8532025\">8532025</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    De Wet CJ, Affleck DG, Jacobsohn E, et al, &quot;Inhaled Prostacyclin Is Safe, Effective, and Affordable in Patients With Pulmonary Hypertension, Right Heart Dysfunction, and Refractory Hypoxemia After Cardiothoracic Surgery,&quot; <i>J Thorac Cardiovasc Surg</i>, 2004, 127(4):1058-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/15052203/pubmed\" target=\"_blank\" id=\"15052203\">15052203</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eronen M, Pohjavuori M, Andersson S, et al, &quot;Prostacyclin Treatment for Persistent Pulmonary Hypertension of the Newborn,&quot; <i>Pediatr Cardiol</i>, 1997, 18(1):3-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/8960484/pubmed\" target=\"_blank\" id=\"8960484\">8960484</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flolan (epoprostenol) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; October 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Golzand E, Bar-Oz B, and Arad I, &quot;Intravenous Prostacyclin in the Treatment of Persistent Pulmonary Hypertension of the Newborn Refractory to Inhaled Nitric Oxide,&quot; <i>Isr Med Assoc J</i>, 2005, 7(6):408-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/15984391/pubmed\" target=\"_blank\" id=\"15984391\">15984391</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Higenbottam TW, Spiegelhalter D, Scott JP, et al, &ldquo;Prostacyclin (Epoprostenol) and Heart-Lung Transplantation as Treatments for Severe Pulmonary Hypertension,&rdquo; Br Heart J, 1994, 70:366-70.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kermode J, Butt W, and Shann F, &quot;Comparison Between Prostaglandin E1 and Epoprostenol (Prostacyclin) in Infants After Heart Surgery,&quot; <i>Br Heart J</i>, 1991, 66(2):175-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/1883670/pubmed\" target=\"_blank\" id=\"1883670\">1883670</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McLaughlin VV, Archer SL, Badesch DB, et al, &ldquo;ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association,&rdquo; <i>Circulation</i>, 2009, 119(16):2250-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/19332472/pubmed\" target=\"_blank\" id=\"19332472\">19332472</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosenzweig EB, Kerstein D, and Barst RJ, &quot;Long-Term Prostacyclin for Pulmonary Hypertension With Associated Congenital Heart Defects,&quot; <i>Circulation</i>, 1999, 99(14):1858-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/10199883 /pubmed\" target=\"_blank\" id=\"10199883 \">10199883 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Veletri (epoprostenol) [prescribing information]. South San Francisco, CA: Actelion Pharmaceuticals US, Inc; June 2012. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Widlitz A and Barst RJ, &quot;Pulmonary Arterial Hypertension in Children,&quot; <i>Eur Respir J</i>, 2003, 21(1):155-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoprostenol-pediatric-drug-information/abstract-text/12570125/pubmed\" target=\"_blank\" id=\"12570125\">12570125</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13139 Version 110.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F165855\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F165856\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1011254\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F13908498\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1011282\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F165839\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F165823\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F11233737\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1011285\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F165850\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1011255\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F5174529\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F165884\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F165844\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F165827\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25872267\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299275\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F165832\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F165834\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2521390\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1011287\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F165826\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F165843\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323130\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038611\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13139|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=epoprostenol-drug-information\" class=\"drug drug_general\">Epoprostenol: Drug information</a></li><li><a href=\"topic.htm?path=epoprostenol-patient-drug-information\" class=\"drug drug_patient\">Epoprostenol: Patient drug information</a></li></ul></div></div>","javascript":null}